Abstract Background Contemporary real-world evidence in advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC) remains limited. This study evaluated real-world treatment patterns and clinical outcomes in patients with advanced GC/GEJC/EAC treated with first-line therapy in the United St...
Jin Gu, S. Mhatre, D. O. Koralek et al.· The Oncologist· 0 citations
BACKGROUND
Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....
K. Kato, J. Ajani, Y. Doki et al.· Annals of Oncology· 2 citations
Esophageal adenocarcinoma (EAC) is a rare and lethal malignancy that evolves through a stepwise mucosal progression — from an intestinal metaplasia known as “Barrett's esophagus (BE)” to low-grade dysplasia (LGD), high-grade dysplasia (HGD), and finally invasive carcinoma — each stage harboring rare clonogenic stem c...
Frank Mckeon, Wa Xian, Ruiwen Zhang et al.· Cancer Research· 0 citations
Findings identify the BAX-SOX9-CDK4 axis as an important mechanism contributing to the antitumor activity of CYD-4-61 and provide a strong preclinical rationale for its further development as a therapeutic strategy for aggressive GAC.
Geng-Yi Zou, Katsuhiro Yoshimura, Yibo Fan et al.· Cancer Letters· 0 citations
This study defines the role of epigenetic reprogramming in BE-to-EAC progression by integrating spatial transcriptomics, single-cell analyses, and functional modeling, and demonstrates that enhancer activation correlates with transitions from stable epithelial identity to highly plastic, dysplastic, and malignant pheno...
Shilpa S. Dhar, J. Ajani· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
